PT  - JOURNAL ARTICLE
AU  - Mélanie Prague
AU  - Linda Wittkop
AU  - Quentin Clairon
AU  - Dan Dutartre
AU  - Rodolphe Thiébaut
AU  - Boris P. Hejblum
TI  - Population modeling of early COVID-19 epidemic dynamics in French regions and estimation of the lockdown impact on infection rate
AID  - 10.1101/2020.04.21.20073536
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.21.20073536
4099  - http://medrxiv.org/content/early/2020/04/24/2020.04.21.20073536.short
4100  - http://medrxiv.org/content/early/2020/04/24/2020.04.21.20073536.full
AB  - We propose a population approach to model the beginning of the French COVID-19 epidemic at the regional level. We rely on an extended Susceptible-Exposed-Infectious-Recovered (SEIR) mechanistic model, a simplified representation of the average epidemic process. Combining several French public datasets on the early dynamics of the epidemic, we estimate region-specific key parameters conditionally on this mechanistic model through Stochastic Approximation Expectation Maximization (SAEM) optimization using Monolix software. We thus estimate basic reproductive numbers by region before isolation (between 2.4 and 3.1), the percentage of infected people over time (between 2.0 and 5.9% as of May 11th, 2020) and the impact of nationwide lockdown on the infection rate (decreasing the transmission rate by 72% toward a Re ranging from 0.7 to 0.9). We conclude that a lifting of the lockdown should be accompanied by further interventions to avoid an epidemic rebound.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported in part by the GESTEPID Inria Mission COVID19.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are available on a github repository https://www.github.com/sistm/SEIRcovid19